Alimera's New 36-Month Safety and Efficacy Results From the Phase 3 Fameā„¢ Study of IluvienĀ® in Patients With Diabetic Macular Edema Presented at the 2011 Arvo Annual Meeting

Ophthalmic biopharmaceutical company Alimera Sciences presented 36-month results from its Phase 3 study treating patients with diabetic macular edema.... [more]

View complete Press Release article